|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.
|
7846046 |
1995 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
|
11248153 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
|
19436038 |
2009 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
|
18768436 |
2008 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
|
15970926 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
|
26124351 |
2015 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
|
19896266 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
16495393 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Gene amplification and expression of the neu (c-erbB-2) sequence in human mammary carcinoma.
|
3412743 |
1988 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
|
16865596 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
|
17614302 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
|
21638049 |
2012 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
We conclude that P-IHC offers a favorable alternative to Southern analysis in the assessment of c-erbB-2 gene copy number of this oncoprotein in human mammary carcinoma.
|
7905629 |
1993 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Amplification of HER-2 oncogene was analysed in DNAs obtained from 291 primary human mammary carcinomas.
|
2915900 |
1989 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
|
20332317 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
|
16234514 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
|
16446318 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
We conclude that IHC offers a favorable alternative to either Southern analysis or Western immunoblotting in the assessment of c-erbB-2 gene copy number and expression levels of oncoprotein in human mammary carcinoma.
|
1979342 |
1990 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
|
22302033 |
2012 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
|
19436038 |
2009 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
15581045 |
2004 |